Edison Investment Research - Universal Biosensors (UBI) QuickView: Better point-of-care diagnostics

Report

Edison Investment Research

QuickView: Better point-of-care diagnostics

Universal Biosensors (UBI) has market-leading technology for point-of-care testing systems, as evidenced by the strong uptake of the OneTouch Verio glucose test strips marketed by LifeScan. The same technology underpins the PT-INR test for coagulation monitoring in warfarin patients that is being sold internationally by partner Siemens, and two additional coagulation tests being developed for Siemens. UBI plans to launch its own point-of-care (PoC) PT-INR test for the patient self-test market in H215.

24/08/2015 2 EN

Underlying

Universal Biosensors

Universal Biosensors is a medical diagnostics company focused on the research, development and manufacture of in vitro diagnostic test devices. Through its subsidiary, Co. conducts research, development and manufacturing activities in Melbourne, Australia. Co.'s focus includes working with Siemens Healthcare Diagnostics Inc. (Siemens) in relation to a range of products for the point-of-care coagulation testing market. The product developed with Siemens is the Xprecia Stride™ Coagulation Analyzer, which has received CE mark approval and U.S. Food and Drug Administration approval. The analyzer is available in Europe, the Middle East, Africa, Asia Pacific, Latin America and Canada.

See profile

AU000000UBI2 Australian Securities Exchange Australia

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Other Reports on these Companies

SmartInsider

Universal Biosensors Inc: 1 director

A director at Universal Biosensors Inc bought 200,000 shares at 0.230AUD and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The na...

Free Trial

December 13, 2022 December 13, 2022 1 EN

Independent Investment Research

Monthly LMI Update Independent Investment Research

Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked. This compares to the total dividends of 5 cents per share in FY20. The Board has confirmed that, in...

August 6, 2021 August 6, 2021 10 EN

Moody's Investors Service

Moody's withdraws Unione di Banche Italiane S.p.A.'s ratings and assessments

Rating Action: Moody's withdraws Unione di Banche Italiane S.p.A.' s ratings and assessments. Global Credit Research- 21 Apr 2021. Senior unsecured rating affirmed at Baa1 with negative outlook.

EUR 168.14

April 21, 2021 April 21, 2021 6 EN

Tortilla Mexican Grill - Cracking on

Notwithstanding its sector ‘sweet spot’ (a healthy, customisable product at a competitive price), Tortilla Mexican Grill (Tortilla) has taken the opportunity of a change in management to refine its strategy to address challenges since its successful IPO in 2021 as well as expedite growth. Significant benefit is expected from a new delivery structure to mitigate commission charges in an important part of the business (c 30% of sales), from enhanced marketing to tackle surprisingly low brand awareness and from an initial director of food to bolster menu development. With a new FY24 target of sel...

4h / 1m 4h / 1m 1 EN

Richard Williamson

Richard Williamson

Vection Technologies - Moving from niche to mainstream markets

Vection’s Q324 update showed strong double-digit growth in revenue and cash receipts, driven by multiple contract wins, including its largest contract to date with an existing defence customer. A swing to positive operating cash flow in Q3 (A$4.1m), coupled with contract wins, validates the company’s streamlined sales structure, designed to bolster operational efficiency. Cash generated also supported a quarter-on-quarter reduction in debt. Management is seeing early positive signs by enhancing the platform’s compatibility with Apple Vision Pro, potentially unlocking a key growth avenue from r...

6h / 25m 6h / 25m 1 EN

Pedro Fonseca

Pedro Fonseca

The Merchants Trust - Celebrating its 135th anniversary

The Merchants Trust’s (MRCH’s) manager, Simon Gergel at Allianz Global investors, is very excited about the number of reasonably priced opportunities available in the UK market. Also, good income generation from the trust’s portfolio of high-quality companies with robust fundamentals enabled MRCH to record another consecutive dividend increase in FY24; it now has a 42-year track record. The trust’s attractive 5.1% dividend yield is one of the highest in the 19-strong AIC UK Equity Income sector and its NAV total return over the last three, five and 10 years is superior versus the peers with a ...

11h / 41m 11h / 41m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN